{
    "2021-10-18": [
        [
            {
                "time": "",
                "original_text": "贝达药业(300558.SZ)：凯铭投资质押的合计780万股延期购回",
                "features": {
                    "keywords": [
                        "贝达药业",
                        "凯铭投资",
                        "质押",
                        "延期购回"
                    ],
                    "sentiment_score": -0.2,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "医药生物行业周报：疫苗加强针接种工作陆续开启 关注三季报业绩预期差投资机会",
                "features": {
                    "keywords": [
                        "医药生物",
                        "疫苗",
                        "加强针",
                        "三季报",
                        "业绩预期差",
                        "投资机会"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "true",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "贝达药业：股东累计质押情况",
                "features": {
                    "keywords": [
                        "贝达药业",
                        "股东",
                        "质押"
                    ],
                    "sentiment_score": -0.3,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "贝达药业：两款产品均用于治疗非小细胞肺癌，但所针对的患者靶点不同",
                "features": {
                    "keywords": [
                        "贝达药业",
                        "非小细胞肺癌",
                        "靶点"
                    ],
                    "sentiment_score": 0.4,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "",
                "original_text": "医药生物行业周报：季度业绩波动该如何应对",
                "features": {
                    "keywords": [
                        "医药生物",
                        "季度业绩",
                        "波动",
                        "应对"
                    ],
                    "sentiment_score": 0.1,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            }
        ]
    ]
}